These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 36010986)
1. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. Shinkawa T; Ohuchida K; Nakamura M Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010986 [TBL] [Abstract][Full Text] [Related]
2. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer. Yu Y; Schuck K; Friess H; Kong B Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383 [TBL] [Abstract][Full Text] [Related]
3. BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma. Gao B; Hu G; Sun B; Li W; Yang H J Transl Med; 2024 Oct; 22(1):937. PubMed ID: 39402590 [TBL] [Abstract][Full Text] [Related]
4. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030 [TBL] [Abstract][Full Text] [Related]
5. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Liu H; Shi Y; Qian F Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881 [TBL] [Abstract][Full Text] [Related]
6. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. Neuzillet C; Nicolle R; Raffenne J; Tijeras-Raballand A; Brunel A; Astorgues-Xerri L; Vacher S; Arbateraz F; Fanjul M; Hilmi M; Samain R; Klein C; Perraud A; Rebours V; Mathonnet M; Bièche I; Kocher H; Cros J; Bousquet C J Pathol; 2022 Dec; 258(4):408-425. PubMed ID: 36102377 [TBL] [Abstract][Full Text] [Related]
7. Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics. Ijichi H Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230803 [TBL] [Abstract][Full Text] [Related]
8. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. McAndrews KM; Chen Y; Darpolor JK; Zheng X; Yang S; Carstens JL; Li B; Wang H; Miyake T; Correa de Sampaio P; Kirtley ML; Natale M; Wu CC; Sugimoto H; LeBleu VS; Kalluri R Cancer Discov; 2022 Jun; 12(6):1580-1597. PubMed ID: 35348629 [TBL] [Abstract][Full Text] [Related]
9. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer. Stouten I; van Montfoort N; Hawinkels LJAC Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052 [TBL] [Abstract][Full Text] [Related]
11. Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. Gorchs L; Kaipe H Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203869 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108 [TBL] [Abstract][Full Text] [Related]
14. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Bryce AS; Dreyer SB; Froeling FEM; Chang DK Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358721 [TBL] [Abstract][Full Text] [Related]
15. Medical Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Morgan A; Griffin M; Kameni L; Wan DC; Longaker MT; Norton JA Biology (Basel); 2023 Jul; 12(8):. PubMed ID: 37626931 [TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739 [TBL] [Abstract][Full Text] [Related]
17. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Shinkawa T; Ohuchida K; Mochida Y; Sakihama K; Iwamoto C; Abe T; Ideno N; Mizuuchi Y; Shindo K; Ikenaga N; Moriyama T; Nakata K; Oda Y; Nakamura M J Exp Clin Cancer Res; 2022 Mar; 41(1):89. PubMed ID: 35272688 [TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Geng X; Chen H; Zhao L; Hu J; Yang W; Li G; Cheng C; Zhao Z; Zhang T; Li L; Sun B Front Cell Dev Biol; 2021; 9():655152. PubMed ID: 34336821 [TBL] [Abstract][Full Text] [Related]
20. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Vaish U; Jain T; Are AC; Dudeja V Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]